#For patients
Written for adults considering a peptide as part of their health management.
Oral semaglutide 25 mg vs the injection
A Novo Nordisk funded indirect comparison put oral semaglutide 25 mg against the 2.4 mg injection. The weight-loss gap was about one percentage point.
Orforglipron liver safety: pooled data
A pooled analysis of 11,220 people across seven orforglipron phase 3 trials found no confirmed drug-induced liver injury. Here is what it checked, and did not.
PT-141 vs semaglutide: two brain targets
Both peptides act on brain receptors, and that is where the similarity stops. One is licensed for low sexual desire, the other for weight and heart risk.
Stacking GLP-1 Drugs With Mood Peptides
Tirzepatide and retatrutide users sometimes add peptides like Semax for energy or mood. Here is what the trial evidence actually supports.
AGA MetALD Update: Where GLP-1 Drugs Stand
The AGA's new practice update addresses MetALD, a liver disease combining metabolic risk and alcohol use, and what it says about semaglutide.
CJC-1295 With DAC vs Without DAC
CJC-1295 with DAC and without DAC are chemically different molecules with different half-lives, not two doses of the same peptide.
5mg vs 10mg Vials: What's Actually Missing
CJC-1295 and ipamorelin vial size doesn't decide potency. What's actually missing is any FDA-recognized reconstitution or stability standard for either peptide.
Semaglutide mechanism: the missing pieces
Semaglutide binds a well-mapped receptor, but a 2026 SELECT trial analysis shows weight loss explains only part of its heart benefit.
Semaglutide vs Older Diabetes Drugs
Semaglutide beats DPP-4 inhibitors like sitagliptin in trials, but head-to-head data against sulfonylureas and thiazolidinediones is thin.
Eating disorders in the GLP-1 era
GLP-1 drugs cut binge eating in trials and raise dietary restraint. Here is what clinicians are flagging on eating disorder risk, and what is unmeasured.
GLP-1 Prescribing Without an Indication
A US records study of 92 million adults found GLP-1 prescribing without a documented indication rose 15-fold, and 35.1% of recipients had a normal BMI.
Semaglutide vs orforglipron: who paid?
A new indirect comparison says oral semaglutide beats orforglipron on weight loss. Five of its eight authors work for Novo Nordisk. Here is what it shows.